Dreavia Pharma

Dreavia Pharma is a specialty pharmaceutical company headquartered in Zug, Switzerland, dedicated to providing patients with rare and ultra-rare diseases access to innovative therapies. The company focuses on the EMEA region (Europe, Middle East, and Africa), leveraging a leadership team with deep expertise in orphan drug commercialization from firms like Alexion and Shire. Dreavia operates by partnering with global biotech companies to manage regulatory approval, market access, and distribution of high-need treatments. A notable part of its portfolio includes a partnership with Abeona Therapeutics for the gene therapy EB-101, targeting Recessive Dystrophic Epidermolysis Bullosa. By providing a localized commercial infrastructure, Dreavia ensures that breakthrough medicines reach patients in complex and often overlooked markets.